Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 August 2018, 18:35 HKT/SGT
Share:
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.



Aug 1, 2018 18:35 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Aon announces 7 Best Employers in Singapore for 2018  
Aug 15, 2018 00:00 HKT/SGT
The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease  
Aug 14, 2018 22:50 HKT/SGT
Watts Miners Announces State-of-the-Art Cryptocurrency Mining Technology for BTC, ETH, LTC, DASH and XMR  
Aug 14, 2018 19:30 HKT/SGT
Strong Support to Chong Hing Bank from GZ Metro by Subscription of 70,126,000 New Issued Shares at a Consideration of Approximately HK$1.0 billion  
Aug 14, 2018 18:42 HKT/SGT
DreamEast (593.HK) Tourist Resort Projects To Be Completed  
Aug 14, 2018 18:25 HKT/SGT
Hong Kong Young Fashion Designers' Contest (YDC) 2018 Announces Finalists & Martine Rose as VIP Judge  
Aug 14, 2018 17:30 HKT/SGT
JUMBO Revenue Increases 2.9% to $35.8 Million in Q3 FY2018  
Aug 14, 2018 17:30 HKT/SGT
ETC Singapore clinches four titles at the annual PropertyGuru Myanmar Property Awards Gala 2018  
Aug 14, 2018 17:00 HKT/SGT
InNet.Asia Officially Launches the Registration For "THE NEXT 2018"  
Aug 14, 2018 16:45 HKT/SGT
More than 400 IT professionals joined CLOUDSEC Hong Kong 2018  
Aug 14, 2018 16:30 HKT/SGT
More Press release >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: